ArticleQuantitative imaging in medicine and surgery2026
Artificial intelligence-based prostate cancer risk stratification via large-scale ultrasound images paired with histopathology.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) is primarily screened and diagnosed via prostate-specific antigen (PSA) testing, digital rectal examination (DRE), multiparametric magnetic resonance imaging (mpMRI), and transrectal ultrasound (TRUS). Nevertheless, an open research challenge remains to develop artificial intelligence (AI) tools that enable non-invasive, accurate diagnosis, and risk stratification of PCa. This study aimed to construct an Anatomy-Aware Transformer (AAT) model based on a large-scale dataset of paired TRUS images and corresponding histopathological findings, and to further validate the clinical value of TRUS-based AI for PCa diagnosis and risk stratification. Methods: Sagittal TRUS images were prospectively acquired pre- and intra-biopsy. Based on the intra-biopsy images, the prostate contour and the location of biopsy tissue cores on pre-biopsy images were manually annotated. According to the characteristic features of the prostate and periprostatic tissues, we designed a feature screening module and a feature integration module, and further constructed an AAT model that deeply integrates prostate regional segmentation and PCa diagnosis tasks. The diagnostic performance of the AAT model in PCa detection and risk stratification was evaluated by comparing its results with those of 18 classic models and four ultrasonographers. Results: A Primary Dataset (18,424 images; May 2022 to Dec 2023) supported training/internal validation, and an External Dataset (683 images; Jun to Jul 2024) external validation. The AAT model outperformed all comparison models across all tasks: PCa detection (internal accuracy 0.977 Conclusions: We developed a novel AAT model that exhibits outstanding performance in diagnosing PCa and CSPCa, with reliable efficacy in PCa risk stratification. This non-invasive model effectively improves the diagnostic accuracy of ultrasonographers and enables individualized clinical management for PCa patients with varying risk levels, showing promising clinical translation potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.